^
Association details:
| Biomarker: | EGFR L858R + EGFR T790M |
|---|---|
| Cancer: | Melanoma |
| Drug: | doxorubicin hydrochloride (Topoisomerase II inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Deciphering the molecular mechanism of enhanced tumor activity of the EGFR variant T790M/L858R using melanoma cell lines
Published date:
06/02/2023
Excerpt:
T790M/L858R dramatically triggers phosphorylation of actin cross-linking protein alpha-actinin-4 in the absence of EGF. This double mutant also conferred resistance to a general chemotherapy doxorubicin through Akt but not the p38 signaling pathway….These findings suggest that T790M/L858R not only confers enhanced therapeutic resistance in cancer cell lines but also may promote tumor metastasis.
DOI:
10.3389/fonc.2023.1163504
